We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Systems (VEEV) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
Veeva Systems (VEEV - Free Report) closed at $158.49 in the latest trading session, marking a -1.22% move from the prior day. This change lagged the S&P 500's daily loss of 0.49%. Meanwhile, the Dow lost 0.05%, and the Nasdaq, a tech-heavy index, lost 0.9%.
The provider of cloud-based software services for the life sciences industry's shares have seen a decrease of 8.81% over the last month, not keeping up with the Medical sector's loss of 0.86% and the S&P 500's gain of 12.8%.
Analysts and investors alike will be keeping a close eye on the performance of Veeva Systems in its upcoming earnings disclosure. The company is expected to report EPS of $2.13, up 8.12% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $857.33 million, indicating a 12.95% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $8.81 per share and revenue of $3.59 billion. These totals would mark changes of +8.77% and +12.47%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Veeva Systems. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.73% upward. Veeva Systems is currently a Zacks Rank #1 (Strong Buy).
Investors should also note Veeva Systems's current valuation metrics, including its Forward P/E ratio of 18.2. Its industry sports an average Forward P/E of 23.13, so one might conclude that Veeva Systems is trading at a discount comparatively.
We can additionally observe that VEEV currently boasts a PEG ratio of 0.52. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical Info Systems industry held an average PEG ratio of 1.38.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 90, finds itself in the top 37% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Veeva Systems (VEEV) Declines More Than Market: Some Information for Investors
Veeva Systems (VEEV - Free Report) closed at $158.49 in the latest trading session, marking a -1.22% move from the prior day. This change lagged the S&P 500's daily loss of 0.49%. Meanwhile, the Dow lost 0.05%, and the Nasdaq, a tech-heavy index, lost 0.9%.
The provider of cloud-based software services for the life sciences industry's shares have seen a decrease of 8.81% over the last month, not keeping up with the Medical sector's loss of 0.86% and the S&P 500's gain of 12.8%.
Analysts and investors alike will be keeping a close eye on the performance of Veeva Systems in its upcoming earnings disclosure. The company is expected to report EPS of $2.13, up 8.12% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $857.33 million, indicating a 12.95% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $8.81 per share and revenue of $3.59 billion. These totals would mark changes of +8.77% and +12.47%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Veeva Systems. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.73% upward. Veeva Systems is currently a Zacks Rank #1 (Strong Buy).
Investors should also note Veeva Systems's current valuation metrics, including its Forward P/E ratio of 18.2. Its industry sports an average Forward P/E of 23.13, so one might conclude that Veeva Systems is trading at a discount comparatively.
We can additionally observe that VEEV currently boasts a PEG ratio of 0.52. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical Info Systems industry held an average PEG ratio of 1.38.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 90, finds itself in the top 37% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.